The Victorian government has confirmed it will invest $5 million to support Monash Institute of Pharmaceutical Sciences (MIPS) to manufacture doses of the mRNA vaccine for trials, due to start within months. The novel mRNA-based vaccine will enable a Victorian manufacturer to develop critical manufacturing capability of mRNA vaccines for clinical trials, a level of expertise which is currently unavailable in Australia.
展开▼
